Fulcrum Therapeutics Announces Merger with Slate Medicines, $245M Financing

What Happened
Fulcrum Therapeutics (FULC) filed an 8-K on Aug 17, 2026 reporting that on Aug 16, 2026 it entered a definitive Agreement and Plan of Merger to combine with Slate Medicines (Slate) via a two-step merger structure, intended to qualify as a tax‑free reorganization. The transaction includes a concurrent private financing (the “Concurrent Investment”) of approximately $245.0 million and contemplates changing Fulcrum’s name to “Slate Medicines, Inc.” and a Nasdaq reverse stock split, subject to stockholder approvals and other closing conditions.

Key Details

• Merger terms and ownership: Based on the Exchange Ratio formula, after the Closing and the $245M Concurrent Investment, pre‑Merger Slate stockholders are expected to own ~55.9% of the combined company, the Investors ~39.1%, and pre‑Merger Fulcrum stockholders ~5.0% (fully diluted, subject to adjustments).
• Valuations used in the formula: Fulcrum valued at $31.3M (adjustable for net cash at Closing); Slate valued at $350.0M (exclusive of Concurrent Investment).
• Cash dividend & equity actions: Fulcrum expects to declare a cash dividend of $270M to pre‑Merger Fulcrum stockholders at Closing (subject to adjustment). Fulcrum will seek shareholder approval to issue merger shares, adopt new 2026 equity plans and ESPP, change its name, and effect a reverse stock split.
• Stockholder support, governance and financing: Slate holders representing ~78.65% agreed to support the deal; certain Fulcrum holders (~1.0%) also executed support agreements. The Investors purchase Slate shares immediately prior to the merger (exempt private placement) and Slate agreed to file resale registration rights within 30 business days after the financing.

Why It Matters
This is a transformational transaction: it combines Fulcrum with a much larger Slate (per the valuations used), brings in substantial new cash ($245M) and contemplates a $270M cash dividend to existing Fulcrum holders. The deal will materially change Fulcrum’s ownership, board composition (board expected to be five Slate‑designated members), ticker/name and capital structure (reverse split, new equity plans). Closing is subject to stockholder approvals, regulatory clearances (HSR), Nasdaq and SEC filing/registration requirements, and other customary conditions — so it is not final until those conditions are satisfied.